We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit o... Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. Show more
NGN-401 has been generally well-tolerated by three patients with multiple months of follow-up Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic...
Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position...
Ongoing Phase 1/2 clinical trial for NGN-401 to include additional patients in Cohort 1 and a dose-escalation cohort Both previously planned updates are expected to provide a more robust dataset...
Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological...
Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological...
DSMB clears third pediatric patient for dosing in ongoing NGN-401 Phase 1/2 clinical trial for Rett syndrome; On track to dose third pediatric patient in early 1Q:24 CTA clearance obtained from...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.59 | -5.03961965135 | 31.55 | 33.075 | 28.09 | 75761 | 30.48251288 | CS |
| 4 | -20.78 | -40.9538825384 | 50.74 | 51.22 | 28.09 | 132106 | 39.71849457 | CS |
| 12 | -0.3 | -0.991407799075 | 30.26 | 53 | 28.09 | 139346 | 39.53019459 | CS |
| 26 | 15.39 | 105.628002745 | 14.57 | 53 | 12.49 | 123688 | 36.15154066 | CS |
| 52 | 15.39 | 105.628002745 | 14.57 | 53 | 12.49 | 123688 | 36.15154066 | CS |
| 156 | 15.39 | 105.628002745 | 14.57 | 53 | 12.49 | 123688 | 36.15154066 | CS |
| 260 | 15.39 | 105.628002745 | 14.57 | 53 | 12.49 | 123688 | 36.15154066 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
